Twist Bioscience Corp TWST
We take great care to ensure that the data presented and summarized in this overview for Twist Bioscience Corp is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Top Institutions Holding TWST
View all-
Artisan Partners Limited Partnership Milwaukee, WI6.02MShares$247 Million0.43% of portfolio
-
Vanguard Group Inc Valley Forge, PA5.62MShares$231 Million0.0% of portfolio
-
Black Rock Inc. New York, NY5.42MShares$223 Million0.01% of portfolio
-
Cathie Wood Ark Investment Management LLC | St. Petersburg, Fl5.36MShares$220 Million2.3% of portfolio
-
Invesco Ltd. Atlanta, GA3.64MShares$150 Million0.03% of portfolio
-
William Blair Investment Management, LLC Chicago, IL3.48MShares$143 Million0.4% of portfolio
-
State Street Corp Boston, MA3.17MShares$130 Million0.01% of portfolio
-
Sumitomo Mitsui Trust Holdings, Inc.2.86MShares$118 Million0.09% of portfolio
-
Nikko Asset Management Americas, Inc.2.86MShares$118 Million1.5% of portfolio
-
Jpmorgan Chase & CO New York, NY2.48MShares$102 Million0.01% of portfolio
Latest Institutional Activity in TWST
Top Purchases
Top Sells
About TWST
Twist Bioscience Corporation, a synthetic biology company, manufactures and sells synthetic DNA-based products. The company's DNA synthesis platform enables the manufacturing of synthetic DNA by writing DNA on a silicon chip. It offers synthetic DNA-based products, including synthetic genes, tools for sample preparation, antibody libraries for drug discovery and development, and DNA as a digital data storage medium. The company has collaboration agreements with Victorian Clinical Genetic Services; Vivlion GmbH.; Kyowa Kirin Pharmaceutical Research, Inc.; deepCDR Biologics AG; and Centogene N.V to develop advanced sequencing tools. It also has a research collaboration with Boehringer Ingelheim International GmbH to use proprietary antibody libraries to discover therapeutic antibodies against multiple targets. Twist Bioscience Corporation was incorporated in 2013 and is headquartered in South San Francisco, California.
Insider Transactions at TWST
Insider Transaction List
View all| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Nov 11
2024
|
Robert Chess |
SELL
Open market or private sale
|
Direct |
3,600
-7.39%
|
$169,200
$47.38 P/Share
|
|
Nov 11
2024
|
Robert Chess |
BUY
Exercise of conversion of derivative security
|
Direct |
3,600
+12.48%
|
$28,800
$8.82 P/Share
|
|
Nov 11
2024
|
Emily M. Leproust Chief Executive Officer |
SELL
Open market or private sale
|
Direct |
7,968
-1.35%
|
$382,464
$48.0 P/Share
|
|
Nov 11
2024
|
Paula Green SVP of Human Resources |
SELL
Open market or private sale
|
Direct |
1,347
-1.17%
|
$64,656
$48.0 P/Share
|
|
Nov 11
2024
|
Patrick John Finn President and COO |
SELL
Open market or private sale
|
Direct |
10,340
-4.47%
|
$496,320
$48.0 P/Share
|
|
Nov 11
2024
|
Dennis Cho |
SELL
Open market or private sale
|
Direct |
1,507
-1.63%
|
$72,336
$48.0 P/Share
|
|
Nov 06
2024
|
Dennis Cho |
SELL
Open market or private sale
|
Direct |
1,811
-1.92%
|
$79,684
$44.6 P/Share
|
|
Nov 06
2024
|
Patrick John Finn President and COO |
SELL
Open market or private sale
|
Direct |
6,239
-2.63%
|
$274,516
$44.6 P/Share
|
|
Nov 06
2024
|
Adam Laponis Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
4,160
-4.45%
|
$183,040
$44.6 P/Share
|
|
Nov 06
2024
|
Robert F. Werner Chief Accounting Officer |
SELL
Open market or private sale
|
Direct |
1,448
-3.08%
|
$63,712
$44.6 P/Share
|
|
Nov 06
2024
|
Paula Green SVP of Human Resources |
SELL
Open market or private sale
|
Direct |
5,519
-4.56%
|
$242,836
$44.6 P/Share
|
|
Nov 06
2024
|
Emily M. Leproust Chief Executive Officer |
SELL
Open market or private sale
|
Direct |
14,334
-2.37%
|
$630,696
$44.6 P/Share
|
|
Nov 04
2024
|
Robert F. Werner Chief Accounting Officer |
SELL
Open market or private sale
|
Direct |
156
-0.33%
|
$6,396
$41.56 P/Share
|
|
Nov 04
2024
|
Robert F. Werner Chief Accounting Officer |
BUY
Grant, award, or other acquisition
|
Direct |
8,500
+15.25%
|
-
|
|
Nov 04
2024
|
Adam Laponis Chief Financial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
20,000
+17.64%
|
-
|
|
Nov 04
2024
|
Patrick John Finn President and COO |
SELL
Open market or private sale
|
Direct |
2,681
-1.12%
|
$109,921
$41.56 P/Share
|
|
Nov 04
2024
|
Patrick John Finn President and COO |
BUY
Grant, award, or other acquisition
|
Direct |
80,838
+11.26%
|
-
|
|
Nov 04
2024
|
Emily M. Leproust Chief Executive Officer |
SELL
Open market or private sale
|
Direct |
4,841
-0.8%
|
$198,481
$41.56 P/Share
|
|
Nov 04
2024
|
Emily M. Leproust Chief Executive Officer |
BUY
Grant, award, or other acquisition
|
Direct |
126,809
+9.79%
|
-
|
|
Nov 04
2024
|
Dennis Cho |
SELL
Open market or private sale
|
Direct |
659
-0.69%
|
$27,019
$41.56 P/Share
|
Last 12 Months Summary
| Grant, award, or other acquisition | 401K shares |
|---|---|
| Exercise of conversion of derivative security | 3.6K shares |
| Payment of exercise price or tax liability | 29.3K shares |
|---|---|
| Open market or private sale | 153K shares |
| Grant, award, or other acquisition | 7.85K shares |